Henry Schein (HSIC) Expected to Announce Earnings on Tuesday

Henry Schein (NASDAQ:HSIC) is projected to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Henry Schein to post earnings of $1.30 per share and revenue of $3.3446 billion for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:00 AM ET.

Henry Schein Stock Up 3.6%

Shares of NASDAQ:HSIC opened at $79.57 on Monday. The firm has a fifty day moving average price of $77.37 and a two-hundred day moving average price of $71.67. The company has a market cap of $9.37 billion, a price-to-earnings ratio of 25.18, a PEG ratio of 2.37 and a beta of 0.88. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79. Henry Schein has a one year low of $60.56 and a one year high of $82.80.

Institutional Trading of Henry Schein

Several hedge funds have recently added to or reduced their stakes in the business. Jain Global LLC grew its stake in shares of Henry Schein by 2.0% during the third quarter. Jain Global LLC now owns 10,662 shares of the company’s stock valued at $708,000 after buying an additional 207 shares during the last quarter. Captrust Financial Advisors boosted its holdings in Henry Schein by 3.6% during the 4th quarter. Captrust Financial Advisors now owns 6,105 shares of the company’s stock valued at $461,000 after acquiring an additional 210 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after acquiring an additional 229 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in Henry Schein by 3.2% in the 4th quarter. Daiwa Securities Group Inc. now owns 7,689 shares of the company’s stock worth $581,000 after purchasing an additional 236 shares during the period. Finally, Banco Bilbao Vizcaya Argentaria S.A. lifted its position in Henry Schein by 0.8% in the third quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 32,562 shares of the company’s stock valued at $2,161,000 after purchasing an additional 260 shares during the last quarter. 96.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Barclays began coverage on Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 target price for the company. JPMorgan Chase & Co. boosted their price objective on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Barrington Research set a $79.00 target price on shares of Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Mizuho set a $81.00 target price on shares of Henry Schein and gave the company a “neutral” rating in a research report on Tuesday, January 20th. Finally, Morgan Stanley increased their price target on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a report on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Henry Schein has an average rating of “Hold” and a consensus target price of $76.42.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.